Biogen Defends Controversial Alzheimer's Drug as FDA Calls for Probe
Biogen's new — and controversial — Alzheimer's drug, Adhulem, made a modest $2 million in revenue in the first several weeks after its...
Biogen's new — and controversial — Alzheimer's drug, Adhulem, made a modest $2 million in revenue in the first several weeks after its...